Pen Needles Market

Pen Needles Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Material Type, Device, Functionality, StagePen Needles Market is anticipated to expand from $4.0 billion in 2025 to $7.5 billion by 2035, growing at a CAGR of approximately 6.6%. Insulin pen needles are crucial for insulin injection in people with diabetes. These needles come in various sizes, typically defined by gauge (G) and length. The needles are designed for comfort and efficiency, with coatings like silicone for smooth injections. There are several brands offering insulin pen needles, with prices varying depending on the retailer and the size of the needle. Using savings cards like SingleCare can significantly reduce the cost of these needles.

The price comparison of retail price and singlecare price for pen needles is as follows: The CVS Pharmacy (retail price is US$ 55.56 with single care pricing upto US$ 48.74). Similarly, Walmart pharmacy offers (retail price of pen needles accounting to US$ 59.85 and singlecare pricing to US$39.26). Additionally, Walgreens pharmacy offers (retail price to US$48.44 with singlecare pricing accounting to US$39.26). Furthermore, Kroger Pharmacy offers pen needles (with retail price of US$53.21 and singlecare pricing of US$47.13).

Segment Overview
Based on product, the market is segmented as insulin pen needles, glucagon pen needles, and growth hormone pen needles. The insulin pen needles will account highest revenue and market share accounting to 86.5% in 2024. The insulin pen needle is gaining high adoption among the patients for self-managed diabetes care. Insulin pen needles meet their needs, offering convenience and safety that align with modern diabetes care practices. Additionally, compatibility with insulin pens is another factor driving the adoption. Primarily, there is no need for complex manoeuvring to draw the insulin out of a vial compared to traditional insulin pens. Also, the final dose can be monitored and easy to view due to large number display in the dosing window compared to traditional counting tick marks on the syringe.

On the other hand, based on application, hormone replacement therapy (HRT) will account highest CAGR for pen needles market during the forecast period The rising aging population globally has driven the adoption of pen needles in hormone replacement therapy (HRT). As individuals age, conditions such as menopause in women and testosterone deficiency in men necessitate precise and regular hormone administration, which pen needles efficiently support. Moreover, the preference for at-home HRT is growing, fueled by advancements in pen needle design and the availability of pre-filled hormone pens. Patients seek more control and privacy in their treatment, making pen needles the preferred option for self-administered hormone therapy. The aforementioned factors are responsible for the segmental growth during the forecast period

Geographical Overview
North America will account highest share for the pen needles market during the forecast period Also, the region will account highest market share of 37.4% in 2024. Among the North America region, the US will dominate the pen needles market. Further, the Centers for Disease Control and Prevention (CDC) 2024 report reveals that, around 14.7% of the US adults have diabetes. Also, there are 1.2 million cases of diabetes in the US annually accounting to approximately 5.9 per 1,000 people according to the statistics revealed by the CDC 2024 report. Therefore, with high diabetes incidence in the US adoption of pen needles is high due to associated benefits and comforts after adoption. Such aforementioned factors are responsible for accounting highest share for the pen needles market in the North America region.

Europe holds the second-largest share due to high insulin pen adoption, strong health insurance, and consumer preference for accurate, convenient, and cost-effective devices. Asia Pacific is the fastest-growing region, fueled by a large diabetic population and new product innovations like Terumos FineGlide Sterile Pen Needle. Latin America, led by Brazil, benefits from government programs and WHO-supported initiatives promoting pen needle use. MEA growth is driven by aging populations, healthcare investments, and demand for minimally invasive therapies, with key companies expanding through partnerships and localized production.

Key Trends and Drivers
Increasing Adoption of Pen Needles in Non-Insulin Therapies -
Pen needles are increasingly being used for administering non-insulin injectable therapies, such as GLP-1 receptor agonists for diabetes and obesity, and growth hormones for endocrine disorders. This expanded application is driving demand across various therapeutic areas. According to Diabetes Care Insights revealed that 45% of pen needle usage is now attributed to non-insulin therapies, with a 20% growth in this segment across Asia-Pacific and North America in 2023. Ozempic and Trulicity, These GLP-1 receptor agonists, managed using pen needles, have gained significant growth in managing Type 2 diabetes and obesity, particularly in the U.S. and Canada.
Furthermore, the growing prevalence of chronic conditions requiring injectable therapies is driving the adoption of pen needles in non-insulin treatments. For instance, patients with osteoporosis are increasingly prescribed injectable drugs like teriparatide, which are conveniently administered using pen needles. Similarly, autoimmune diseases such as rheumatoid arthritis and psoriasis, treated with biologics like adalimumab, are fostering demand for these devices due to their precise dosing and ease of use. The versatility of pen needles in accommodating various drug formulations and injection regimens makes them a preferred choice among healthcare providers and patients. Manufacturers are also collaborating with pharmaceutical companies to design pen needles tailored for specific therapies, enhancing their role in non-insulin markets.
Technological Advancements -
Technological advancements in pen needles are poised to revolutionize diabetes care by offering innovative needles with enhanced capabilities. These involve patient safety and treatment & monitoring. Additionally, the integration of smart technologies such as dose tracking, reminders, and mobile app connectivity has the potential to improve usability and adherence to medication regimens. Moreover, Terumo's "FineGlide" is designed as a 3-bevel super sharp needle with high-grade silicone surface. The product encompasses thin wall technology to ensure greater flow rate and provides better penetration requiring less injection force compared to other alternatives available in the market.

RECENT DEVELOPMENTS
In August 2025, Trividia Health launched new product "TRUEplus 5-Bevel Pen Needles in the UK". This new 5-bevel insulin pen needle line gives healthcare providers the ability to provide a variety of different needle gauges and sizes at a low cost to their patients with diabetes.

In July 2025, Apollo Medical launched the new product "Apollo Pro-Shield Duo Safety Pen Needles" in the UK. These needles feature a dual safety mechanism to reduce the risk of accidental needle injuries. The product is available in two sizes: 4mm/31G and 5mm/30G making them the most cost-effective dual safety insulin pen needles on the national drug tariff by 25%.

In April 2025, Owen Mumford launched new product "UnifineOTC Pen Needles". UnifineOTC eliminates the complexities of insurance billing, offering a reliable solution for patients with high copayments, high deductibles, or who are uninsured or underinsured. By removing coverage-related barriers, pharmacies can support patients more efficiently and ensure access to high-quality diabetes care products.

In November 2024, evercare medical launched a new product "evercare pen needles". This new product provide a superior experience for patients with type I diabetes who use insulin pens.

In March 2024, Hindustan Syringes and Medical Devices (HMD has introduced Dispojekt, an innovative single-use syringe with a safety needle, in Bhopal. This launch supports Indias vision of becoming a self-reliant hub for medical device manufacturing and exports. Dispojekt is designed to reduce accidental needle stick injuries (NSIs) among healthcare workers, lowering infection risks and associated costs. By minimizing disposal and training expenses, the syringe is expected to deliver long-term financial benefits to the healthcare sector while enhancing workplace safety. HMDs initiative aligns with Indias efforts to strengthen its position as a global leader in medical devices.

KEY PLAYERS
Ypsomed, HTL- Strefa, Terumo, Owen Mumford, Artsana Group, B. Braun Melsungen, Ulticare, Allison Medical, Stat Medical, Jiangsu Delfu, Jiangsu Jichun, Nipro, Vitrex Medical, Delfin Technologies, Arkray, Medexel, Promisemed, Hindustan Syringes, KDL Medical, Shanghai Kindly

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation. Show more